Hypoglycemia Clinical Trial
Official title:
Dose Response Oxidation of a Sweet-corn Derived Polysaccharide (PhytoSpherix) During Exercise in Endurance Trained Athletes
PhytoSpherix (Phx) is an all-natural, edible polysaccharide extracted from sweet corn. This carbohydrate is the major muscle fuel for intense exercise and its stores are quite small such that one can run out of it during a single exercise bout. Therefore, Phx should provide significant exercise fuel if consumed during exercise. As a result its intake could enhance intense exercise performance by providing additional fuel. This experiment Will investigate the effects of 4 different dosages of Phx consumed throughout a prolonged exercise bout on carbohydrate and fat utilization as well as its oxidation rate and perception of effort during prolonged intense exercise in trained cyclists. Muscle and liver carbohydrate stores will be examined using a non-invasive ultrasound technique.
Status | Not yet recruiting |
Enrollment | 8 |
Est. completion date | September 2017 |
Est. primary completion date | September 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 30 Years |
Eligibility |
Inclusion Criteria: - Healthy male endurance trained athletes with >2 y cycling experience; about 2 h/day Exclusion Criteria: - Unhealthy athletes, smokers |
Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Canada | Exercise Nutrition Research Laboratory, Western University | London | Ontario |
Lead Sponsor | Collaborator |
---|---|
University of Western Ontario, Canada | Mirexus Biotechnologies Inc |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Oxidation of PhytoSpherixat | Breath samples will be taken starting at 0, 15, 30, 45, 60, 75, 90, 135, up to 150 min from the beginning of the exercise session to measure change in oxidation of PhytoSpherix | 0, 15, 30, 45, 60, 75, 90, 135, 150 min from the beginning of the exercise session | No |
Primary | Noninvasive ultrasound measure of glycogen in Vastus lateralis, rectus femoris and liver | Change in muscle and liver glycogen will be measured 10 min before and 10 min after exercise session. When muscle and liver glycogen content is high, the ultrasound image is hypoechoic (dark), and with glycogen depletion and water loss, the image is hyperchoic (brighter).Three ultrasound measurements at each site will be made by a trained technician using a 12 MHz linear transducer and a standard diagnostic high resolution GE LOGIQ-e ultrasound machine (GE Healthcare, Milwaukee, WI). After calculating statistics on the color bar to determine the general brightness settings of the machine, images will be pre-processed and segmented to isolate the muscle area under analysis using a center crop within the muscle section 25 mm from the top muscle sheath. Comparing these results will help better understand the effect of supplementation of Phx at different rates on any changes in glycogen stores of muscle and liver. | 10 min before and 10 min after the 150 min exercise session | No |
Secondary | blood glucose concentration | Changes in blood glucose will be measured at 0, 15, 30, 45, 60, 75, 90, 135, 150 min from the beginning of the exercise session. A blood drop by finger prick approach starting at time 0, 15, 30, 45, 60, 75, 90, 135, 150 min from the beginning of the exercise session under sterile practice will be used to determine blood glucose concentrations | 0, 15, 30, 45, 60, 75, 90, 135, 150 min from the beginning of the exercise session | No |
Secondary | blood lactate concentration | Changes in blood lactate will be measured at 0, 15, 30, 45, 60, 75, 90, 135, 150 min from the beginning of the exercise session. A blood drop by finger prick approach starting at time 0, 15, 30, 45, 60, 75, 90, 135, 150 min from the beginning of the exercise session under sterile practice will be used to determine blood lactate concentrations | 0, 15, 30, 45, 60, 75, 90, 135, 150 min from the beginning of the exercise session | No |
Secondary | Respiratory exchange ratio | Respiratory exchange ratio will be measured at 0, 15, 30, 45, 60, 75, 90, 135, 150 min from the beginning of the exercise session for periods of 4 min by using an online automated gas-analysis system. | At 0, 15, 30, 45, 60, 75, 90, 135, 150 min from the beginning of the exercise session | No |
Secondary | rate of perceived exertion | rate of perceived exertion (RPE) for whole body and legs will be measured at 0, 15, 30, 45, 60, 75, 90, 135, 150 min from the beginning of the exercise session on a scale from 6 to 20, using the Borg category scale. | At 0, 15, 30, 45, 60, 75, 90, 135, 150 min from the beginning of the exercise session | No |
Secondary | questionnaire to rate possible gastrointestinal (GI) problems | every athlete will be asked at 30, 60, 90, 120 and 150 min from the beginning of the exercise session to fill in a questionnaire to rate possible gastrointestinal (GI) problems including stomach problems, GI cramping, bloated feeling, diarrhea, nausea, dizziness, headache, belching, vomiting, and urge to urinate and defecate. While cyclists are on the bike and continue their exercise, each question will be answered by simply ticking a box on the questionnaire that corresponds to the severity of the GI problem addressed. The items will be scored on a 10-point scale (1 not at all, 10 very, very much). | At 30, 60, 90, 120 and 150 min from the beginning of the exercise session | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03482154 -
Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
|
||
Completed |
NCT03667053 -
Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
|
Phase 3 | |
Active, not recruiting |
NCT03422471 -
Hypoglycemia and Autonomic Nervous System Function- B2
|
N/A | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05597605 -
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects
|
N/A | |
Not yet recruiting |
NCT05990933 -
Role of Adrenaline in in the Inflammatory Response in Diabetes
|
N/A | |
Withdrawn |
NCT03736083 -
Introducing CGM at Type 1 Diabetes Diagnosis
|
N/A | |
Completed |
NCT02966275 -
Post Bariatric Closed Loop Glucagon Trial
|
N/A | |
Withdrawn |
NCT02518022 -
How to be Safe With Alcoholic Drinks in Diabetes
|
N/A | |
Completed |
NCT02213003 -
Allogeneic Islet Cells Transplanted Onto the Omentum
|
Phase 1/Phase 2 | |
Completed |
NCT01176656 -
Hypoglycemia: Physician and Patient Perspectives
|
N/A | |
Completed |
NCT01147276 -
Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes
|
Phase 4 | |
Completed |
NCT00998374 -
Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge
|
N/A | |
Terminated |
NCT01225159 -
Tight Glycaemic Control During Cardiac Surgery
|
N/A | |
Completed |
NCT00373854 -
Study of How Low Blood Sugar Affects the Way Blood Vessels Work
|
N/A | |
Completed |
NCT00285233 -
Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes
|
Phase 1/Phase 2 | |
Recruiting |
NCT05916131 -
Pilot Feasibility Study for HypoPals, a Mobile Health Program for Improving Hypoglycemia Management.
|
N/A | |
Terminated |
NCT04026750 -
Insulin Tolerance Test Study in Patients With Type 1 Diabetes
|
Phase 1 | |
Completed |
NCT05133765 -
The SMART B Exercise Study :''The SMART Study''
|
N/A | |
Recruiting |
NCT04192422 -
DiGESTnewborn Study
|